Institut National De La Sante Et De La Recherche Medicale

Mayo Foundation for Medical Education and Research

Medical Research Council

Institut Clayton De La Recherche

Other

Biomerieux, Inc.

Institut National De La Recherche Agronomique

The Institute of Cancer Research: Royal Cancer Hospital

Genetic Therapy, Inc.

Ecole Normale Superieur De Lyon

L'universite Pierre Et Marie Curie

Francois-Loic Cosset

Stephen James Russell

Frances Joanne Morling

Roberto Cattaneo

Adele Kay Fielding

Robin Anthony Weiss

Mary Katharine Collins

Francois Mallet

Didier Trono

Yasuhiro Takeuchi

Els Verhoeyen

Virginie Sandrin

Dimitri Lavillette

Michael Pensiero

David Klatzmann

Jean-Loup Salzmann

Jacques Samarut

Patrick Salmon

Bertrand Bellier

Pierrick Thoraval

Gerard Verdier

Didier Poncet

Caroline Costa

Cecilia Frecha

Frances Joanne Bullough

Miloud Benchaibi

Pierre Savatier

Bertrand Boson

Victor-Marc Nigon

Yahia Chebloune

Charlotte Fribert

Mustapha Belakebi

Astrid Reyss-Brion

Catherine Legras

Didier Negre

Claude Bagnis

Jean-Luc Blond

Olivier Bouton

Alessia Ruggieri

Birke Bartosch

Anais Girard-Gagnepain

Mary K L Collins

The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.

Synthetic viruses and uses thereof

The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least:

Vector particles for targeting CD34+ cells

The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:&#x2014;a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or&#x2014;a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.

Lentiviral vectors pseudotyped with mutant BaEV glycoproteins

A method is provided for producing a recombinant pseudotyped viral vector particle wherein a cell is transfecting with (i) at least one vector construct; (ii) at least one packaging construct; and (iii) an expression construct encoding a chimeric glycoprotein encoded by a nucleic acid comprising the sequence of SEQ ID NO: 1 to yield a producer cell, followed by culturing the producer cell in a medium; and separating the producer cell from the medium to recover the recombinant viral vector particle from the medium. Vectors obtained in this manner have significantly higher titers than vectors coated with the parental non-chimeric glycoprotein.

Chimeric glycoproteins and pseudotyped lentiviral vectors

The present invention provides improved chimeric glycoproteins (GPs) and improved lentiviral vectors pseudotyped with those glycoproteins. Also provided are methods and compositions for making such glycoproteins and vectors, and improved methods of in vitro and in vivo transduction of cells with such vectors. Improved chimeric GPs encode the extracellular and transmembrane domains of GALV or RD114 GPs fused to the cytoplasmic tail of MLV-A GP. Vectors pseudotyped with these GAL V/TR and RD 114/TR GP chimeras have significantly higher titers than vectors coated with the parental GPs. Additionally, RD114/TR-pseudotyped vectors are efficiently concentrated and are resistant to inactivation induced by the complement of both human and macaque sera. RD114 GP-pseudotyped lentiviral vectors have particular utility for in vivo gene transfer applications.

Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.

Compositions and methods for elimination of unwanted cells

A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the group consisting of: a peptide comprising the cyt domain of the envelope protein of the human endogenous retrovirus, HERV-W; a peptide comprising amino acids 448-538 of SEQ ID NO: 1; and a peptide comprising a sequence having, for any series of 20 amino acids, at least 80% identity with amino acids 448-538 of SEQ ID NO: 1. Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation.

Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein

The invention relates to the generation and the use of pestivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of pestivirus virion.

Infectious pestivirus pseudo-particles containing functional Erns, E1, E2 envelope proteins

Retroviral vectors which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.

Retroviral vectors produced by producer cell lines resistant to lysis by human serum

The invention relates to a recombinant viral particle capable of delivering a nucleic acid to mammalian cells, the particle including a member of a first specific binding pair capable of binding to a first receptor expressed on the surface of a cell so as to cause infection thereof, and a surface-exposed member of a second specific binding pair capable of binding to a second receptor generally not expressed on the surface of the cell, such that binding of the viral particle to the second receptor via the member of the second specific binding pair inhibits infection of the cell by the viral particle.

Delivery of nucleic acids

Retroviral which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.

Retroviral vectors produced by producer cell lines resistant to lysis by

Growing community of inventors

Lyons, France

Francois-Loic Cosset